| abstract |
The present invention provides a novel diaryl ether derivative as a β 2 adrenergic receptor agonist. The present invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β 2 adrenergic receptor activity, and useful for preparing such compounds. Process and intermediates are provided. New β 2 adrenergic receptor agonists are provided that have improved properties such as improved duration, potency, selectivity and / or initiation of action. |